상세 보기
Which biomarker is useful to evaluate as a treatment outcome in spondyloarthritis?
- Lee, Sang-Hoon;
- Kim, Tae Hwan
Citations
SCOPUS
0초록
Although the etiology of ankylosing spondylitis is unknown, it is necessary to develop tools for evaluating the patient response to the new therapeutic drugs. AS is mediated by chronic inflammation and characterized by bone destruction and formation. Recently, tumor necrosis factor-alpha (TNF-alpha) blockade has been widely used for treatment of AS, and the patient response is evaluated by examining the levels of various biomarkers such as matrix metalloproteinases (MMPs), interleukins (ILs), and vascular endothelial growth factor (VEGFs). This review discusses the recent studies suggesting candidate biomarkers for evaluation of the response to treatment and the joint remodeling markers.
키워드
Ankylosing spondylitis; Biomarkers; Spondyloarthritis; TNF-alpha blockade; biological marker; C reactive protein; cathepsin K; cytokine; etanercept; infliximab; interleukin 17; interleukin 1beta; interleukin 23; interleukin 6; matrix metalloproteinase; osteocalcin; osteoclast differentiation factor; osteogenic protein 1; stromelysin; transforming growth factor beta; tumor necrosis factor alpha; tumor necrosis factor alpha inhibitor; vasculotropin; ankylosing spondylitis; bone regeneration; bone remodeling; cytokine production; cytokine release; disease activity; erythrocyte sedimentation rate; human; osteoclast; osteolysis; outcome assessment; pathogenesis; priority journal; protein blood level; protein expression; protein function; review; treatment duration
- 제목
- Which biomarker is useful to evaluate as a treatment outcome in spondyloarthritis?
- 저자
- Lee, Sang-Hoon; Kim, Tae Hwan
- 발행일
- 2009-08
- 유형
- Review
- 권
- 5
- 호
- 3
- 페이지
- 165 ~ 168